David Gass is a registered patent attorney for biotechnology companies, pharmaceutical companies, diagnostics companies, universities, and research institutions, helping clients develop and implement IP strategies to protect and commercialize life-improving biotechnology inventions. He assists clients with patentability analyses, drafting and prosecuting patent applications, and maximizing patent term and patent life-cycle for products. He also assists clients with freedom-to-operate issues relative to the IP rights of others. He has experience with appeals and inter partes proceedings before the U.S. Patent and Trademark Office, including interferences, reexamination and reissue proceedings. Mr. Gass also assists clients with international patent portfolio management and licensing, and advises counsel in foreign patent prosecution and opposition proceedings. He has lectured students and industry in the United States and Europe on intellectual property matters, including chairing of panels at the 2010-2013 BIO International Conventions on "IP Issues Affecting Biomarker-Based Diagnostics." In recognition of his outstanding patent work in life sciences, Mr. Gass has been featured as a "Life Sciences Star" in LMG Life Sciences, 2012-2016. He was selected by his peers for inclusion in the 2016 and 2017 editions of The Best Lawyers in America© in the practice area of Patent Law, was named "Biotechnology & Life Sciences Patent Lawyers of the Year – USA" in the Corporate LiveWire 2016 Legal Awards, and was recognized in 2015 by the Corporate LiveWire Legal Awards in the "Excellence in Patent Prosecution – Illinois" category. Mr. Gass has also been selected by the Chicago Law Bulletin’s Leading Lawyer Network as a “Leading Lawyer."
Mr. Gass has assisted clients with intellectual property in a wide variety of biotechnology disciplines, including the following: Recombinant DNA, protein, and antibody technologies; Therapeutic antibodies, including humanized antibodies; Genomics, proteomics, and epigenetics; Medical diagnostic and prognostic tests, reagents, and kits that use genomic, metabolomic, and traditional markers to diagnosis disease or identify susceptibility, for diseases such as cancers, cardiovascular disease, and diabetes; products and therapies involving the microbiome; Angiogenesis and anti-angiogenesis technologies and circulatory disorders; Gene therapy, interfering RNA, CRISPR, and antisense technologies; Vaccines and adjuvants, including cancer vaccines; Genetic modification of plants and animals, including transgenic organisms; Cancer diagnosis and therapies, and oncogenes; Anti-viral therapies, including protease inhibitors; Polymerase chain reaction and mass spectrometry; Nanotechnology and industrial biopolymers; Prions, Alzheimer's disease, and neural regeneration; Inflammation and arthritis; Metabolic diseases and diabetes; Therapeutic methodologies and formulations; Stem cell therapies; Food and beverage formulations.